Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).

Publication

Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).

Journal Paper/Review - Jul 23, 2022

Schmulenson Eduard, Bovet Cédric, Theurillat Regula, Decosterd Laurent Arthur, Largiadèr Carlo R, Prost Jean-Christophe, Csajka Chantal, Bärtschi Daniela, Guckenberger Matthias, von Moos Roger, Bastian Sara, Jörger Markus, Jaehde Ulrich

Citation

Schmulenson E, Bovet C, Theurillat R, Decosterd L, Largiadèr C, Prost J, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Jörger M, Jaehde U. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). Br J Clin Pharmacol 2022; 88:5336-5347.

Type

Journal Paper/Review (English)

Journal

Br J Clin Pharmacol 2022; 88

Publication Date

Jul 23, 2022

Issn Electronic

1365-2125

Pages

5336-5347

Brief description/objective

Locally advanced rectal cancer (LARC) is an area of unmet medical need with one third of patients dying from their disease. With response to neoadjuvant chemo-radiotherapy being a major prognostic factor, trial SAKK 41/16 assessed potential benefits of adding regorafenib to capecitabine-amplified neoadjuvant radiotherapy in LARC patients.